Business Context and Reporting Period
This Form 8-K is a current report filed by Xcyte Therapies, Inc. (not Bio Green Med Solution, Inc.) on September 8, 2004, covering events occurring on September 2, 2004. The registrant is a Delaware corporation headquartered in Seattle, Washington.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes and compensation policy amendments.
Material Changes
- Board Election: Daniel K. Spiegelman was elected as a Director effective September 2, 2004. He will serve on the Audit and Compensation Committees.
- Stock Option Grant: Mr. Spiegelman was granted an option to purchase 10,000 shares of common stock, vesting over two years. This grant is subject to stockholder approval.
- Compensation Policy Amendments: The Board amended the 2003 Directors' Stock Option Plan and adopted a new director compensation policy in June 2004.
Guidance, Outlook, and Management Commentary
The filing details specific changes to director compensation and equity incentives:
- Option Grant Increases: Initial option grants for non-employee directors increased from 4,545 to 10,000 shares (vesting shortened from three to two years). Annual grants increased from 1,818 to 10,000 shares (vesting increased from one to two years).
- Committee Incentives: Committee chairs and Audit Committee members receive an additional annual grant of 2,500 shares vesting over two years.
- Cash Compensation: Non-employee directors are entitled to a $20,000 annual retainer, plus $1,000 per in-person board meeting, $500 per telephonic board meeting, and $500 per committee meeting.
- Approval Status: Amendments to the Directors' Plan and the grant to Mr. Spiegelman require stockholder approval at the next annual meeting.
Investor Verification Checklist
- Verify the outcome of the stockholder vote on the amended Directors' Plan and Mr. Spiegelman's option grant at the next annual meeting.
- Confirm the total number of shares reserved under the amended Directors' Plan to assess potential dilution.
- Review the attached press release (Exhibit 99.1) for additional context on Mr. Spiegelman's background and qualifications.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.